Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + tuvonralimab with regorafenib in previously treated rare digestive system tumors
ChiCTR2500096704Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Feb 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of iparomlimab, tuvonralimab and regorafenib in anal squamous cell carcinoma (SCCA), peritoneal mesothelioma and peritoneal carcinomatosis (PC) (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Objective response rate. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabregorafenib
03
Conditions
anal squamous cell carcinoma (SCCA)peritoneal mesotheliomaperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on ChiCTR2500096704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096704.